Entrada Therapeutics, Inc.
NASDAQ:TRDABiotechnology
+$0.03 today
- Market cap
- $196.93M
- Beta
- -0.26
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$3.97
Volume 0.82M
Average 0.36M
TRDA Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Entrada Therapeutics, Inc.NASDAQ: TRDA
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 17.5% from a year ago
Property, plant & equipment (net) stood at $65.26M at the end of Q1 FY2026, down 17.5% from a year earlier and down 3.7% from the prior quarter. Over 3 fiscal years it compounded at +27.1% a year.
Context
- Property, plant & equipment (net) amounted to 19.5% of total assets at the end of Q1 FY2026, up 3.2 pp from a year earlier.
- Property, plant & equipment (net) increased in 1 of the last 3 fiscal years.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -17.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 67.76M USD
- Year-over-year change
- -17.4%
- 4-year CAGR
- +81.4%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.76M | -17.4% |
| FY2024 | 2024-12-31 | 82.05M | -11.5% |
| FY2023 | 2023-12-31 | 92.68M | +180.7% |
| FY2022 | 2022-12-31 | 33.02M | +427.4% |
| FY2021 | 2021-12-31 | 6.26M | — |
Property, Plant & Equipment (Net) vs competitors
How TRDA compares with its peers on the latest reported figures
- TRDA's Mar 2026 property, plant & equipment (net) of $65.26M is the 3rd highest of the 11 companies compared; the peer median is $32.96M.
- Its year-over-year change of -17.5% is the 8th highest of 11, against a peer median of -5.9%.
- Property, plant & equipment (net) amounts to 19.5% of total assets for TRDA, versus a peer median of 7.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $4.17B | +89896.8% | -9.7% | 1.9% | |
| Mar 2026 | $108.84M | -14.3% | -16.9% | 27.5% | |
| Mar 2026 | $65.26M | -17.5% | +27.1% | 19.5% | |
| Mar 2026 | $46.08M | +23.2% | -1.6% | 41.7% | |
| Mar 2026 | $41.66M | +473.7% | +38.2% | 12.8% | |
| Mar 2026 | $39.43M | -14.4% | +7.7% | 18.0% | |
| Mar 2026 | $26.5M | -23.4% | -14.8% | 10.8% | |
| Mar 2026 | $14.07M | +12.7% | +7.2% | 3.2% | |
| Mar 2026 | $831K | -55.4% | -35.6% | 0.3% | |
| Mar 2026 | $49K | -53.8% | -19.6% | 0.1% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $39K | +2.6% | -28.3% | 0.0% |
| Peer median (excluding TRDA) | $32.96M | -5.9% | -12.2% | 7.0% | |
Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 291.06M | 45.16M | 67.6M | 101.21M | 90.39M |
| Short-term Investments | 0 | 143.56M | 284.37M | 318.79M | 205.3M |
| Net Receivables | 0 | 0 | 5.88M | 3.68M | 2.58M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 21.16M | 11.92M | 16.36M | 7.98M |
| Total Current Assets | 298.7M | 209.88M | 369.77M | 440.04M | 306.25M |
| Property, Plant & Equipment (Net) | 6.26M | 33.02M | 92.68M | 82.05M | 67.76M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 872K | 9.16M | 6.74M | 4.23M | 3.36M |
| Total Non-current Assets | 7.13M | 42.18M | 99.42M | 86.28M | 71.13M |
| Total Assets | 305.83M | 252.06M | 469.19M | 526.32M | 377.38M |
| Account Payables | 706K | 5.99M | 3.28M | 4.26M | 2.29M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 4.02M | 667K | 0 |
| Deferred Revenue | 0 | 0 | 132.26M | 13.65M | 342K |
| Other Current Liabilities | 4.56M | 5.49M | 7.66M | 8.43M | 9.22M |
| Total Current Liabilities | 6.72M | 21.97M | 158.8M | 39.48M | 24.45M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 7.72M | 6.51M | 0 |
| Other Non-current Liabilities | 396K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 396K | 17.53M | 68.04M | 58.16M | 46.79M |
| Total Liabilities | 7.12M | 39.5M | 226.83M | 97.64M | 71.25M |
| Common Stock | 3K | 3K | 3K | 4K | 4K |
| Retained Earnings | (93.67M) | (188.29M) | (194.97M) | (129.34M) | (273.09M) |
| Accumulated OCI | 0 | (2.06M) | 195K | (43K) | 652K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 298.72M | 212.55M | 242.36M | 428.68M | 306.13M |
| Total Debt | 0 | 25.94M | 68.23M | 59.21M | 50.93M |
| Net Debt | (291.06M) | (19.22M) | 628K | (42M) | (39.46M) |
Entrada Therapeutics, Inc.
NASDAQ:TRDA
Intrinsic Alpha fair value
Locked
Current Price
$5.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.